I. Bargagna

Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC

P. Ferrari, A. Nicolini, C. Scatena, 2022, International journal of molecular sciences.

PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.

R. Danesi, F. Cucchiara, M. Del Re, 2020, Pharmacological research.

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients

R. Danesi, M. Del Re, S. Crucitta, 2023, Cancers.

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib

C. Porta, L. Livi, R. Danesi, 2022, Breast.